Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Elagolix Advancement Buoys Neurocrine Biosciences

November 1, 2011 6:47 am | News | Comments

Neurocrine Biosciences Inc. said that third-quarter jumped sharply as revenue nearly tripled as the company recognized $30 million in revenue for moving a new drug closer to regulatory approval.


Consumer Advocates Push J & J on Shampoo Ingredients

November 1, 2011 6:39 am | News | Comments

Two chemicals considered harmful to babies remain in Johnson & Johnson's baby shampoo sold in the U.S. and some other countries, even though the company already makes versions without them.


Pfizer Profits Triple for the Quarter

November 1, 2011 6:36 am | News | Comments

Drugmaker Pfizer Inc. beat Wall Street expectations with higher profit and revenue in the third quarter, the last before generic competition starts wiping out sales of Lipitor, the cholesterol blockbuster that has buoyed the company for years.


Newron Exploring Options for Safinamide

October 31, 2011 11:18 am | News | Comments

Newron has regained the global commercial rights to safinamide, its lead treatment for Parkinson’s disease. Currently in late Phase 3 worldwide development, safinamide provides the company with substantial opportunities.


Repligen Buying Novozymes Biopharma

October 31, 2011 11:07 am | News | Comments

Repligen Corporation announced the execution of a definitive agreement to acquire the business of Novozymes Biopharma Sweden AB in a cash transaction of $22.7 million and future potential milestone payments of $5.6 million.


AgonOx Partnering with MedImmune

October 31, 2011 11:04 am | News | Comments

AgonOx announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform.


NuMe Files Patent App for NM504

October 31, 2011 11:00 am | News | Comments

NuMe Health LLC announced that its has filed a patent application covering a proprietary formulation of its first cobiotic product, NM504, which is being developed for the prediabetic population.


FDA Approves Exparel for Postsurgical Pain

October 31, 2011 10:32 am | News | Comments

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration has approved Exparel 1.3% for administration into the surgical site to produce postsurgical analgesia.


Endocycle Has Implications for Medicine

October 31, 2011 10:03 am | News | Comments

An international team of researchers has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth’s biomass.


FDA Backs Vytorin for Kidney Disease

October 31, 2011 9:57 am | News | Comments

The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.


Multilabel Microplate Reader

October 31, 2011 8:04 am | Product Releases | Comments

LabLogic Systems has released its Chameleon V multilabel microplate reader for researchers using fluorescence and luminescence for bio-analysis.


RNA Isolation Kit

October 31, 2011 7:50 am | Drug Discovery & Development | Product Releases | Comments

G-Biosciences' GET Total RNA Kit isolates total RNA from contaminating DNA, proteins, and nucleases in under 60 minutes using a simple three step protocol. The kit is compatible with numerous species and tissues.


MonoSol Amends Lawsuit Against BioDelivery

October 31, 2011 7:36 am | News | Comments

MonoSol Rx, LLC, the developer of PharmFilm drug delivery technology, announced that it has filed a second amended complaint in its litigation against BioDelivery Sciences International, Inc. and its development partners.


Study Creates Tool for Cancer Drug Development

October 31, 2011 7:29 am | News | Comments

Scientists have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases.


Revalesio Presenting RNS60 Data at ACAAI

October 31, 2011 7:15 am | News | Comments

RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the Phase 1 study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.